Med-Mastodon

Giuseppe Michieli''To date, <a href="https://mstdn.science/tags/tixagevimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#tixagevimab</a>-cilgavimab cannot be considered a substitute for <a href="https://mstdn.science/tags/vaccination" class="mention hashtag" rel="nofollow noopener" target="_blank">#vaccination</a> but may be a useful supporting <a href="https://mstdn.science/tags/therapy" class="mention hashtag" rel="nofollow noopener" target="_blank">#therapy</a> if the recommended dose for pre-exposure prophylaxis is doubled.''

Giuseppe MichieliImpaired neutralizing <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="nofollow noopener" target="_blank">#antibody</a> <a href="https://mstdn.science/tags/efficacy" class="mention hashtag" rel="nofollow noopener" target="_blank">#efficacy</a> of <a href="https://mstdn.science/tags/tixagevimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#tixagevimab</a>-cilgavimab 150+150 mg as pre-exposure <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener" target="_blank">#prophylaxis</a> against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener" target="_blank">#BA5</a>. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: <a href="https://doi.org/10.1016/j.jcv.2023.105584" rel="nofollow noopener" target="_blank">https://doi.org/10.1016/j.jcv.2023.105584</a> <a href="https://mstdn.science/tags/reseach" class="mention hashtag" rel="nofollow noopener" target="_blank">#reseach</a> <a href="https://mstdn.science/tags/science" class="mention hashtag" rel="nofollow noopener" target="_blank">#science</a> <a href="https://mstdn.science/tags/medicine" class="mention hashtag" rel="nofollow noopener" target="_blank">#medicine</a> <a href="https://mstdn.science/tags/mAbs" class="mention hashtag" rel="nofollow noopener" target="_blank">#mAbs</a> <a href="https://mstdn.science/tags/betacoronavirus" class="mention hashtag" rel="nofollow noopener" target="_blank">#betacoronavirus</a> <a href="https://mstdn.science/tags/sarbecovirus" class="mention hashtag" rel="nofollow noopener" target="_blank">#sarbecovirus</a> <a href="https://mstdn.science/tags/covid19" class="mention hashtag" rel="nofollow noopener" target="_blank">#covid19</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Breakthrough" class="mention hashtag" rel="nofollow noopener" target="_blank">#Breakthrough</a> <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Infections" class="mention hashtag" rel="nofollow noopener" target="_blank">#Infections</a> in the PROVENT <a href="https://mstdn.science/tags/Prevention" class="mention hashtag" rel="nofollow noopener" target="_blank">#Prevention</a> Trial Were Not Associated with AZD7442 (<a href="https://mstdn.science/tags/Tixagevimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Tixagevimab</a>/Cilgavimab) Resistant Variants <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1" rel="nofollow noopener" target="_blank">https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad210/7191107?rss=1</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Genotypic" class="mention hashtag" rel="nofollow noopener" target="_blank">#Genotypic</a> and Predicted <a href="https://mstdn.science/tags/Phenotypic" class="mention hashtag" rel="nofollow noopener" target="_blank">#Phenotypic</a> <a href="https://mstdn.science/tags/Analysis" class="mention hashtag" rel="nofollow noopener" target="_blank">#Analysis</a> of <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener" target="_blank">#SARS</a>-COV-2 <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/Subvariants" class="mention hashtag" rel="nofollow noopener" target="_blank">#Subvariants</a> in Immunocompromised Patients with <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener" target="_blank">#COVID19</a> Following <a href="https://mstdn.science/tags/Tixagevimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Tixagevimab</a>-Cilgavimab Prophylaxis <a href="https://www.sciencedirect.com/science/article/pii/S1386653223000057?dgcid=rss_sd_all" rel="nofollow noopener" target="_blank">https://www.sciencedirect.com/science/article/pii/S1386653223000057?dgcid=rss_sd_all</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Safety" class="mention hashtag" rel="nofollow noopener" target="_blank">#Safety</a>, Tolerability and Pharmacokinetics of Half-Life Extended <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener" target="_blank">#SARS</a>-CoV-2 Neutralizing Monoclonal <a href="https://mstdn.science/tags/Antibodies" class="mention hashtag" rel="nofollow noopener" target="_blank">#Antibodies</a> <a href="https://mstdn.science/tags/AZD7442" class="mention hashtag" rel="nofollow noopener" target="_blank">#AZD7442</a> (<a href="https://mstdn.science/tags/Tixagevimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Tixagevimab</a> / <a href="https://mstdn.science/tags/Cilgavimab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Cilgavimab</a>) in Healthy Adults <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1" rel="nofollow noopener" target="_blank">https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1</a>

Recent searches

Search options

Administered by:

Server stats:

#tixagevimab